AU5397300A - Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water - Google Patents
Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in waterInfo
- Publication number
- AU5397300A AU5397300A AU53973/00A AU5397300A AU5397300A AU 5397300 A AU5397300 A AU 5397300A AU 53973/00 A AU53973/00 A AU 53973/00A AU 5397300 A AU5397300 A AU 5397300A AU 5397300 A AU5397300 A AU 5397300A
- Authority
- AU
- Australia
- Prior art keywords
- insoluble
- water
- pharmaceutical composition
- active substances
- hardly soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013543 active substance Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19925290 | 1999-06-02 | ||
| DE1999125290 DE19925290A1 (en) | 1999-06-02 | 1999-06-02 | Stable, well-tolerated composition for intranasal administration of water-insoluble drugs e.g. scopolamine, comprising solution of drug in neutral oil, especially triglyceride |
| DE1999136543 DE19936543A1 (en) | 1999-08-03 | 1999-08-03 | Composition for intranasal administration of water-insoluble drugs, e.g. scopolamine, budesonide or diazepam, comprising a solution of the water-insoluble or sparingly water-soluble drug in a neutral oil e.g. a triglyceride |
| DE19936543 | 1999-08-03 | ||
| PCT/EP2000/004799 WO2000074651A1 (en) | 1999-06-02 | 2000-05-26 | Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU5397300A true AU5397300A (en) | 2000-12-28 |
Family
ID=26053616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU53973/00A Abandoned AU5397300A (en) | 1999-06-02 | 2000-05-26 | Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1185246A1 (en) |
| JP (1) | JP2004525854A (en) |
| AU (1) | AU5397300A (en) |
| WO (1) | WO2000074651A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044356A1 (en) * | 2001-04-20 | 2003-03-06 | Jin Auh | Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one) |
| DE10136228A1 (en) * | 2001-07-25 | 2003-03-06 | Wolfgang KOX | Receptor-adapted nicotine supply through anticholinergic and noradrenergic blockade |
| WO2004073632A2 (en) * | 2003-02-19 | 2004-09-02 | Biovail Laboratories Inc. | Rapid absorption selective 5-ht agonist formulations |
| ITMI20032054A1 (en) | 2003-10-22 | 2005-04-23 | Monteres S R L | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL SUSPENSIONS TO BE INHALED. |
| GB0400804D0 (en) | 2004-01-14 | 2004-02-18 | Innoscience Technology Bv | Pharmaceutical compositions |
| EP1981476A2 (en) * | 2006-02-09 | 2008-10-22 | Schering Corporation | Pharmaceutical formulations |
| GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
| DE202010012096U1 (en) * | 2010-09-02 | 2010-11-11 | Lorentz, Eckart, Dr. med. | nose drops |
| CN109758435A (en) * | 2017-11-09 | 2019-05-17 | 郑州泰丰制药有限公司 | Omeprazole aerosol and preparation method thereof |
| WO2024026463A1 (en) * | 2022-07-28 | 2024-02-01 | Happy Healing Inc. | Composition for nasal delivery of an active compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69129110T2 (en) * | 1990-05-10 | 1998-12-10 | Bechgaard International Research And Development A/S, Hellerup | PHARMACEUTICAL PREPARATION CONTAINING N-GLYCOFUROLE AND N-ETHYLENE GLYCOL |
| AU2017592A (en) * | 1991-06-10 | 1993-01-12 | Schering Corporation | Non-chlorofluorocarbon aerosol formulations |
| NZ334913A (en) * | 1996-10-01 | 2001-03-30 | Smithkline Beecham Plc | Use of mupirocin (pseudomonic acid) for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms effective as a sprayable topical agent |
-
2000
- 2000-05-26 EP EP00938686A patent/EP1185246A1/en not_active Withdrawn
- 2000-05-26 JP JP2001501188A patent/JP2004525854A/en active Pending
- 2000-05-26 AU AU53973/00A patent/AU5397300A/en not_active Abandoned
- 2000-05-26 WO PCT/EP2000/004799 patent/WO2000074651A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004525854A (en) | 2004-08-26 |
| EP1185246A1 (en) | 2002-03-13 |
| WO2000074651A1 (en) | 2000-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0103575A3 (en) | Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use | |
| AU5440901A (en) | Cosmetic and/or pharmaceutical preparations | |
| IL144508A0 (en) | Compositions and methods for use in targeting vascular destruction | |
| HUP0300318A3 (en) | Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use | |
| HUP0201214A3 (en) | Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use | |
| PL348193A1 (en) | Self-emulsifying compositions for drugs poorly soluble in water | |
| HUP0202501A3 (en) | Pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use | |
| AU2001272937A1 (en) | Localized molecular and ionic transport to and from tissues | |
| AU1939801A (en) | In situ bioreactors and methods of use thereof | |
| HUP0203588A3 (en) | Analgesic pharmaceutical compositions and their use | |
| AUPQ010299A0 (en) | Improvements in or relating to trading and settlement | |
| AU4303600A (en) | Pharmaceutical composition in unit form containing acetylsalcylic acid and clopidogrel hydrogenosulphate | |
| HUP0203575A3 (en) | Pharmaceutical compositions containing th2 differentiation inhibitors and their use | |
| AU5326100A (en) | Pharmaceutical compositions and methods for use | |
| AU3731400A (en) | Methods and compositions useful in inhibiting apoptosis | |
| HUP9902655A3 (en) | Pharmaceutical composition of hedgehog proteins and use thereof | |
| AU3240000A (en) | Hydrophobic and particulate soil removal composition | |
| AU2300001A (en) | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease | |
| AU1164601A (en) | Therapeutic use and formulation | |
| AU5397300A (en) | Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water | |
| PL349193A1 (en) | Branched chain amino acid−dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy | |
| AP2001002371A0 (en) | Streptogramin derivatives preparation and compositions containing them | |
| AU7651100A (en) | Pharmaceutical and/or cosmetical compositions | |
| HUP0200468A3 (en) | Resorcinol derivatives and pharmaceutical compositions containing them | |
| AU2438400A (en) | Cosmetic and/or pharmaceutical preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |